Cellectar Biosciences, Inc. — 2013 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2013. This is an annual filing, not a standalone fourth-quarter report. The company was named Novelos Therapeutics, Inc. until February 11, 2014.
Business context and pipeline
Cellectar is a development-stage biopharmaceutical company developing cancer imaging and treatment candidates based on its phospholipid ether targeting platform. It reported no product revenue and had not commercialized a product.
- I-124-CLR1404: PET imaging candidate; investigator-sponsored Phase 1/2 trials were ongoing across solid tumors. Initial imaging observations were described as positive, but were preliminary.
- I-131-CLR1404: Radiotherapeutic candidate; enrollment in a Phase 1b dose-escalation trial ended in November 2013. Dose-limiting hematologic toxicities appeared in the third cohort; complete results were expected in early 2014.
- CLR1502: Preclinical optical imaging candidate. The company anticipated filing an IND in 2014.
Legacy compounds NOV-002 and NOV-205 were no longer being developed after prior trials failed to demonstrate efficacy.
Financial performance and liquidity
| Metric | 2013 | 2012 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Operating expenses | $12.40 million | $8.75 million |
| Loss from operations | $12.40 million | $8.75 million |
| Net loss | $10.78 million | $8.80 million |
| Net loss per share | $0.19 | $0.23 |
| Cash used in operating activities | $9.15 million | $6.59 million |
Research and development expense rose 33.9% to $6.86 million, mainly from CLR1502 preclinical work, manufacturing activity, staffing and patent costs; clinical project costs declined. General and administrative expense increased 22.4% to $4.45 million. The company recorded $1.10 million of restructuring costs, principally option modifications, severance and retention. No meaningful operating margin was reported because the company had no product revenue.
Cash and cash equivalents were $2.42 million at year-end, down from $4.68 million. Current assets were $2.77 million and current liabilities were $4.52 million; reported working capital was negative $1.76 million. Total liabilities were $5.12 million, including a $3.36 million derivative liability and $450,000 of Wisconsin Department of Commerce notes. Stockholders’ equity was $1.70 million, versus $10.16 million a year earlier.
In February 2014, after year-end, the company raised $4.00 million gross through convertible debentures and warrants. Management said year-end cash plus these proceeds would fund operations at budgeted levels through June 2014. The debentures bear 8% interest, mature February 6, 2016, and are convertible at $0.50 per share; the warrants cover up to 8 million shares at $1.00 per share, subject to conversion-related conditions.
Material changes and unusual items
- The 2013 net loss increased by about $1.99 million, while loss per share narrowed to $0.19 from $0.23, partly reflecting a higher weighted-average share count.
- A $2.37 million gain on revaluation of derivative warrants reduced reported net loss; the company also recorded a $745,000 loss on issuance of derivative warrants. These are valuation and issuance items, not operating revenue.
- The February 2013 public offering generated approximately $4.98 million in net proceeds and increased shares outstanding by 11 million during the year.
- In October 2013, the company received a waiver allowing $1.878 million of previously restricted financing proceeds to be used for operations rather than planned manufacturing-facility construction.
- Management and board leadership changed substantially in 2013. The company appointed Simon Pedder acting CEO, restructured its board, and began relocating executive functions from Massachusetts to Madison, Wisconsin.
Outlook, risks and contingencies
The auditor’s report includes a going-concern explanatory paragraph, citing recurring losses and a $51.06 million accumulated deficit. The company expects continued operating losses and needs additional capital beyond June 2014; it said it had not entered negotiations for further financing and gave no assurance that funding would be available. The filing notes potential dilution, senior debt claims, and restrictions on certain company actions under the February 2014 debentures.
Key business risks include clinical failure or safety issues, regulatory delays, patient-enrollment and manufacturing constraints, dependence on outside collaborators and contract manufacturers, inability to secure financing, competition, reimbursement uncertainty, and limited commercial capabilities. The Phase 2 glioblastoma imaging trial began enrolling in March 2014, with completion by year-end 2014 expected only subject to additional funding. The company also anticipated filing a CLR1502 IND in 2014; these are forward-looking plans, not achieved outcomes.
A legacy dispute with ZAO BAM remained on appeal. The company said it did not expect the matter to materially affect its financial position, results or cash flows. Management reported effective internal control over financial reporting and effective disclosure controls as of December 31, 2013; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Whether the company secured financing after the reported February 2014 placement and how long available cash ultimately supported operations.
- Full Phase 1b I-131-CLR1404 results, particularly the hematologic toxicities and implications for dose selection and future trials.
- Enrollment, funding, safety and efficacy results for I-124-CLR1404 trials and progress toward the CLR1502 IND.
- The terms, covenants, potential repayment obligations and dilution associated with the convertible debentures, warrants and outstanding derivative instruments.
- Whether the company’s clinical manufacturing arrangements, regulatory pathway and licensing/IP position can support later-stage development.